According to the official website of the General Administration of Market Supervision, recently the General Administration of Market Supervision announced the 2021 people's livelihood field case investigation and handling of the "iron fist" action.
Typical cases (the fourth batch), in which "Guangdong Province, Guangzhou City, Tianhe District Market Supervision Bureau investigated and dealt with the Guangzhou Misheng special medical beauty clinic limited company released illegal medical toxic drug ads case" is listed as one of the typical cases.
The case shows that, in the early days, Tianhe District Market Supervision Bureau received a report that Guangzhou Misheng Special Medical Beauty Clinic Limited is suspected of releasing illegal advertisements for face-slimming injections through online stores , and the Tianhe District Market Supervision Bureau law enforcement officers immediately carried out on-site inspections on the company.
After investigation, the party since February 2020 through the Internet to open "DR REBORN medical beauty flagship store" sales of medical beauty programs. In the sale of "DR REBORN China face-slimming needle to remove wrinkles and improve the bite muscle small V face shoulder thinning needle leg thinning needle medical aesthetic" project, the release of "domestic face-slimming needle" "Hengli face-slimming needle" involving The advertisements are actually "Hengli brand injectable botulinum toxin type A".
According to the "Notice on the Inclusion of Botulinum Toxin Type A in the Management of Toxic Drugs" (SFDA [2008] No. 405), Botulinum Toxin Type A has been included in the management of toxic drugs. Modern Advertising" query the relevant documents found that in 2008, the State Ministry of Health, the State Food and Drug Administration (SFDA) jointly issued "on the inclusion of botulinum toxin type A in the management of toxic drugs notice", botulinum toxin type A and its preparations included in the management of toxic drugs, and stipulates that the drug wholesale enterprises can only be A-type botulinum toxin preparations sold to the medical institutions, without the designated drug business It also stipulates that drug wholesale enterprises can only sell Botulinum toxin A preparations to medical institutions, and that unauthorized drug dealers are not allowed to purchase or sell Botulinum toxin A preparations, and that drug retailers are not allowed to retail Botulinum toxin A preparations. The illegal production, operation and use of A-type botulinum toxin units and individuals, according to the law, severely investigated and dealt with.
The parties released illegal advertisements of toxic drugs for medical use, violating the provisions of Article 15(1) of the Advertising Law of the People's Republic of China*** and the People's Republic of China. Article 15 of the Advertising Law provides that narcotic drugs, psychotropic drugs, toxic drugs for medical use, radiopharmaceuticals and other special drugs, drug-type toxic chemicals, as well as drugs, medical devices and treatments for drug addiction treatment shall not be advertised. Prescription drugs other than those stipulated in the preceding paragraph can only be advertised in the health administrative department of the State Council and the State Council drug supervision and management department **** with the designated medical and pharmacy professional publications.
The Market Supervision Bureau of Tianhe District ordered the party to stop publishing false and illegal advertisements, and imposed administrative penalties on the party according to the law . On May 20, 2021, the Guangzhou Tianhe District Market Supervision Bureau imposed a fine of 200,000 yuan on Guangzhou Meishengzhuan Medical Beauty Clinic Limited for the illegal act of publishing advertisements of toxic drugs for medical use.
The General Administration of Market Supervision (GAMS) said that toxic drugs for medical use, narcotic drugs, psychotropic drugs, radiopharmaceuticals and other special drugs, on the one hand, are necessary for medical activities, and their proper use is conducive to the treatment of diseases and alleviation of patients' pain; on the other hand, they are potentially very harmful, and their improper use may lead to addiction, damage to health, and even jeopardize the safety of life, and they should be subject to the strictest management.
Market Supervision and Regulation Department.
The market supervision department will strictly investigate and deal with the advertising behavior of such special drugs, and maintain the advertising market order.